Adherium Outlines Commercial Progress and Value-Based Care Strategy
· smallcaps.com.au
Adherium shifts to recurring respiratory care as RPM revenue surges 9.4x; 5,300 devices shipped, 2,600+ active patients, US$55/mo, targeting 10,000 by year-end.
Adherium (ASX: ADR) has outlined its progress from a connected-device developer towards a commercial respiratory care business built around recurring patient re...